BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 20855641)

  • 1. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.
    Fritsche HM; Burger M; Dietmaier W; Denzinger S; Bach E; Otto W; Doblinger M; Schwarz S; Buchner H; Hartmann A
    Am J Clin Pathol; 2010 Oct; 134(4):597-603. PubMed ID: 20855641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
    Lotan Y; Bensalah K; Ruddell T; Shariat SF; Sagalowsky AI; Ashfaq R
    J Urol; 2008 Jun; 179(6):2164-9. PubMed ID: 18423745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicolor fluorescence in situ hybridization assay: A monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: A prospective study.
    Galván AB; Salido M; Espinet B; Placer J; Pijuan L; Juanpere N; Lloreta J; Solé F; Gelabert-Mas A
    Cancer Cytopathol; 2011 Dec; 119(6):395-403. PubMed ID: 21717592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vysis UroVysion for the detection of urothelial carcinoma.
    Halling KC
    Expert Rev Mol Diagn; 2003 Jul; 3(4):507-19. PubMed ID: 12877389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate-risk urothelial carcinoma: an unresolved problem?
    Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
    Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
    Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
    J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
    Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
    Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?
    Bollmann M; Heller H; Bánkfalvi A; Griefingholt H; Bollmann R
    BJU Int; 2005 Jun; 95(9):1219-25. PubMed ID: 15892805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.
    Yoder BJ; Skacel M; Hedgepeth R; Babineau D; Ulchaker JC; Liou LS; Brainard JA; Biscotti CV; Jones JS; Tubbs RR
    Am J Clin Pathol; 2007 Feb; 127(2):295-301. PubMed ID: 17210520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
    Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
    Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer.
    Gudjónsson S; Isfoss BL; Hansson K; Domanski AM; Warenholt J; Soller W; Lundberg LM; Liedberg F; Grabe M; Månsson W
    Eur Urol; 2008 Aug; 54(2):402-8. PubMed ID: 18082934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
    Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
    Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
    Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
    J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in cases of equivocal urinary cytology.
    Huysentruyt CJ; Baldewijns MM; Rüland AM; Tonk RJ; Vervoort PS; Smits KM; van de Beek C; Speel EJ
    Histopathology; 2011 Jun; 58(7):1048-53. PubMed ID: 21707706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice.
    Laudadio J; Keane TE; Reeves HM; Savage SJ; Hoda RS; Lage JM; Wolff DJ
    BJU Int; 2005 Dec; 96(9):1280-5. PubMed ID: 16287445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
    Bubendorf L; Piaton E
    Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.